Quantisnow Logo
Dashboard

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

$DNA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $DNA alert in real time by email

BOSTON, Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT (1:30 p.m. ET).

Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-43rd-annual-jp-morgan-healthcare-conference-302346539.html

SOURCE Ginkgo Bioworks

Get the next $DNA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DNA

DatePrice TargetRatingAnalyst
5/15/2024Neutral → Sell
BTIG Research
5/10/2024Mkt Perform → Underperform
William Blair
11/14/2023$3.50 → $2.50Outperform → Mkt Perform
Raymond James
11/9/2023Buy → Neutral
BTIG Research
6/2/2023$3.00 → $1.25Neutral → Sell
Goldman
5/11/2023Outperform → Mkt Perform
William Blair
11/29/2022$6.00Buy
Berenberg
10/4/2022$5.00Equal-Weight
Morgan Stanley
More analyst ratings

$DNA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

    Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

    BOSTON, Feb. 21, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and Ginkgo Bioworks, (NYSE:DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto. It allows us to keep our operating costs low and access multiple sequencing technologies and chemistries on the same platform," said Alex Plocik, Senior Director of Genomics at Ginkgo Bioworks. "In our short-read sequencing workflow, we often pool thousands of individual sam

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

    International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON, Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European C

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$DNA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DNA
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$DNA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DNA
 SEC Filings

See more

$DNA
 Leadership Updates

Live Leadership Updates

See more

  • Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

    Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

    Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

    The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.

    $DNA
    $ILMN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

$DNA
 Financials

Live finance-specific insights

See more

  • Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

    Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

    Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON, Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

    Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck  BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.

    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$DNA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more